SV104 Delivery™ Human CD4 T cell targeted

SunVax is a pioneering biotechnology company located in the Greater Boston area, specializing in the development of advanced lipid nanoparticle (LNP) delivery systems and self-amplifying mRNA (samRNA) platforms. Leveraging a proprietary library of over one million molecular structures, SunVax has synthesized and screened more than 60,000 ionizable lipids through high-throughput methods. To accelerate progress in the mRNA research community, SunVax launched a series of ready-to-use human Hematopoietic Stem cell (HSC) specific delivery LNP kits for research use only for proof-of-concept and screening mRNA constructs ex vivo (in human PBMC cells).

Human CD4 T cell targeted SV104 Delivery™ Kit information and Supporting Data

Table 1. The Characterizations of human CD4 T cell targeted LNP-mRNA generated by SV104 Delivery^™ Kit

The kit exhibits consistently high encapsulation efficiency (>95%), generate nanoparticles with a uniform average size of approximately 100 nm, and maintain a low polydispersity index (PDI).

Figure 1. Stability of human CD4 T cell targeted LNP-mRNA generated by SV104 Delivery™ Kit. The human CD4 T cell targeted LNP-mRNA underwent three freeze–thaw cycles prior to transfect human PBMC cells. Shown are nanoparticle size (A) and polydispersity index (PDI) (B), and transfection efficiency in human PBMC cells (C).  

Figure 2. The SV104 Delivery™ kit demonstrated strong transfection efficacy and cell type specificity in human CD4 T cells. In vitro transfection efficacy: human CD4 T cells were transfected with mRNA encoding eGFP using SV104 Delivery™ kit as indicated. Shown are FACS plots (A) and GFP⁺ cells percentage (B) one day post-transfection determined by flow cytometer.